title: Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of urinary kallidinogenase for recombinant tissue-type plasminogen activator (rt-PA) intravenous thrombolytic treatment in patients with acute cerebral infarction.
  
  
  METHODS
  All 200 patients with acute cerebral infarction were randomized 1:1 into an experimental group (100 cases) and a control group (100 cases). Patients in the control group were administrated rt-PA (0/9 mg/kg) while patients in the experimental group were given urinary kallidinogenase by intravenous drip (0.15 PNAU/d, for 7 days) after rt-PA intravenous thrombolytic treatment (0.9 mg/kg). The main evaluation index was NIHSS and BI.
  
  
  RESULTS
  Compared to the control group, the NIHSS scores were significantly lower 7 and 90 days after thrombolytic therapy (t = 2.391, 2.714; p < 0.05). BI scores were obviously higher at 90 days after thrombolytic therapy in the experimental group (t = 2.675, p < 0.05).
  
  
  CONCLUSIONS
  Urinary kallidinogenase may improve the treatment effect for rt-PA intravenous thrombolytic treatment in patients with acute cerebral infraction.
authors: Department of Neurology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin, China. peilanzhng@sina.com.
authors: Y-X
authors: YX
authors: Wang
authors: Y
authors: Y
authors: Chen
authors: C-H
authors: CH
authors: Zhang
authors: C-H
authors: CH
authors: Li
authors: Z
authors: Z
authors: Dong
authors: S-N
authors: SN
authors: Zhao
authors: Z
authors: Z
authors: Wang
authors: F-F
authors: FF
authors: Zhang
authors: X-G
authors: XG
authors: Tong
authors: J-H
authors: JH
authors: Wang
authors: P-L
authors: PL
authors: Zhang
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000209:etiology / Q000652:urine*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007610:Kallikreins / Q000008:administration & dosage* / Q000652:urine*; D008297:Male; D008875:Middle Aged; D015912:Thrombolytic Therapy / Q000639:trends*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D007610:Kallikreins; D010959:Tissue Plasminogen Activator